Emerging concepts in the management of the malignant haematological disorders

Bibliography

• Textbook of Malignant Haematology. Degos L, Linch DC,Lövenberg B (Eds.), Martin Dunitz, London, UK (1999)1–944.
   Google Scholar
• HANDE KR: Principles and pharmacology ofchemotherapy. In: Wintrobe's Clinical Hematology (Edition 10). Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (Eds.), Williams & Wilkins, Baltimore, USA (1999):2077–2101.
   Google Scholar
• VERWEIJ J, STOTER G: Principles of systemic therapy ofcancer. In: Textbook of Medical Oncology. Cavalli F, Hansen HH, Kaye SB (Eds.), Martin Dunitz, London, UK (1997):23–40.
   Google Scholar
• SKIPPER HE, SCHABEL FM, WILCOX WS: Experimentalevaluation of potential anticancer agents XIII, on the criteria and kinetics associated with curability of experimental leukaemia. Cancer Chemother. Rep. (1964) 34:1–24.
   PubMedGoogle Scholar
• KALLIANPUR A: Supportive care in hematologic malignancies. In: Wintrobe's Clinical Hematology (Edition 10). Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (Eds.), Williams & Wilkins, Baltimore, USA (1999):2102–2156.
   Google Scholar
• HUGHES WT, ARMSTRONG D, BODEY GP et al.: Consensus report: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis. (1997) 25:551–573.
   PubMed Web of Science ®Google Scholar
• •A wide ranging review for clinial use.
   Google Scholar
• VISCOLI C, CASTAGNOLA E: Planned progressive antimicrobial therapy in neutropenic patients. Br. J. Haematol. (1998) 102:879–899.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J: Science and pragmatism in the treatment and prevention of neutropenic infections./ Antimicrob. Chemother. (1998) (Suppl. D):13–24.
   Google Scholar
• ANAISSIE EJ, VARTIVARIAN S, BODEY PG et al.: Random-ized comparison between antibiotics alone and antibi-otics plus granulocyte-macrophage colony stimulating factor (Escbericbia co/i-delivered) in cancer patients with fever and neutropenia. Am.J.Med. (1995) 100:17–23.
   Web of Science ®Google Scholar
• LYMAN GH, KUDERE NM, BALDUCCI L: Economic impact of granulopoiesis simulating agents on the management of febril neutropenia. Curr. Opin. Oncol. (1998) 10:291–296.
   PubMedGoogle Scholar
• PAVLETIC ZS, BIERMAN PJ, ARMITAGE JO: Dose response and dose escalation. In: Textbook of Malignant Haematology. Degos L, Linch DC, Lövenberg B (Eds.), Martin Dunitz, London, UK (1999):281–298.
   Google Scholar
• O'REILLY RJ, PAPADOPAULOS EB, SMALL TN. Allogeneicbone marrow transplantation. In: Textbook of Malignant Haematology. Degos L, Linch DC, Lövenberg B (Eds.), Martin Dunitz, London, UK (1999):315–381.
   Google Scholar
• MCSWEENEY PA, STORB R: Mixed chimerism: preclinical studies and clinical application. Biol. Bone Marrow Transplant. (1999) 5:192–203.
   PubMedGoogle Scholar
• •An excellent paper within this field.
   Google Scholar
• O'BRIEN S, KANTARJIAN HM, KOLLER C et al.: Sequentialhomoharringtonine and interferon-a in the treatment of early chronic phase chronic myelogenous leukemia. Blood (1999) 93:4149–4153.
   Google Scholar
• KANTARJIAN HM, O'BRIEN S, KEATING M et al.: Results ofdecitabine therapy in accelerated blastic phase of chronic myelogenous leukemia. Leukemia (1997) 11:1617–1620.
   Google Scholar
• MCLAUGHLIN P, HAGEMEISTER FB, ROMAGUERA JE etal.: Fludarabine, mitoxantrone and dexamethasone, an effective new regime for indolent lymphoma trial. J. Clin. Oncol. (1996) 14:1262–1268.
   Google Scholar
• BERNELL P, OHM L: Promising activity of gemcitabinein refractory high-grade non-Hodgkin's lymphoma. Br. J. Haematol. (1998) 101:203–204.
   PubMed Web of Science ®Google Scholar
• AKAO Y, MIZOGUCHI H, KOJIMA S, NAOE T, OHISHI N,YAGI K: Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro, activation of caspases and downregulation of bc1-2. Br. J. Haematol. (1998) 102:1055–1060.
   PubMed Web of Science ®Google Scholar
• MAKI A, DIWAKARAN H, REDMAN B et al.: The bc1-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolostatin in human diffuse large cell lymphoma. Anti-Cancer Drug (1995) 6:392–397.
   PubMed Web of Science ®Google Scholar
• WANG H, CHOW DA: Protein kinase C expression links natural antibody binding with surveillance of activated and preneoplastic cells. Scand. J. Immunol. (1999) 49:381–390.
   PubMed Web of Science ®Google Scholar
• WANG Q, FAN S, EASTMAN A, WORLAND PJ, SAUSVILLE EA, O'CONNOR PM: UCN-01, a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (1996) 17:956–965.
   Google Scholar
• BYRD JC, SHINN C, WASELENKO JK et al.: Flavopiridol induces apoptosisin chronic lymphocytic leukaemia cells via activation of caspase-3 without evidence of bc1-2 modulation or dependence on functional p53. Blood (1998) 92:3804–3816.
   PubMed Web of Science ®Google Scholar
• SENDEROWICZ AM. Cyclin-dependent kinase modula-tors as novel therapeutic approaches for hemato-logical malignancies. In: American Society of Hematology Education Program Book. Schechter GP, Hoffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999):454–462.
   Google Scholar
• SHINN C, BYRD JC, RAJI R et al.: Depsipeptides is selectively cytotoxic toward human chronic lympho-cytic leukemia cells and favorably alters the bd-2:BAX ratio and p27 expression with concomitant cleavage of caspase 3. Blood (1998) 90:103a. Abstract 422.
   Google Scholar
• D'AMORE RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• KNELLER R, RAANANI P, HARDAN I et al.: Therapy withthalidomide in refractory multiple myeloma patients, the revival of on old drug. Br. J. Haematol. (2000) 108:391–393.
   PubMed Web of Science ®Google Scholar
• SYKES M, SZOT GL, SWENSON KA, PEARSON DA: Induction of high levels of allogeneric hemotopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Med. (1997) 3:783–787.
   PubMed Web of Science ®Google Scholar
• KHOURI IF, KEATING M, KORBLING M et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneric blood progenitor-cell transplantation as treatment for lymphoid malignancy. J. Clin. Oncol. (1998) 16:2817–2824.
   PubMed Web of Science ®Google Scholar
• SLAVIN S, NAGLER A, NAPARSTEK E et al.: Nonmyeloab-lativ stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplanta-tion with lethal cytoreduction for treatment of malignant and nonmalignant hematologic diseases. Blood (1998) 91:756–763.
   PubMed Web of Science ®Google Scholar
• Appropriate uses of human immunoglobulin in clinical practice: memorandum from IUIS/WHO meeting. WHO Bull. (1982) 60:43–47.
   PubMed Web of Science ®Google Scholar
• AVRAMEREAS S, TERNYNCK T: The natural autoanti-bodies system: between hypothesis and facts. Mol. Immunol. (1993) 30:1133–1142.
   PubMed Web of Science ®Google Scholar
• •This review article provides an excellent summary.
   Google Scholar
• REICHLIN M: Autoantibodies to ubiquitous intracellular antigens interact with living cells. Immunologist (1998) 6:76–78.
   Google Scholar
• KAVERI SV, LACROIX-DESMAZES S, MOUTHON L, KAZATCHKINE MD: Human natural autoantibodies: lessons from physiology and prospects for therapy. Immunologist (1998) 6:227-233. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• OCHSENBEIN AF, FEHR T, LUTZ C et al.: Control of earlyviral and bacterial distribution and disease by natural antibodies. Science (1999) 286:2156–2159.
   PubMed Web of Science ®Google Scholar
• MEISSNER HC, SCHLIEVERT PM, LEUNG DYM: Mechanisms of inimunoglobulin action: observations in Kawasaki syndrome and RSV prophylaxis. Immunol. Rev. (1994) 139:109–123.
   PubMed Web of Science ®Google Scholar
• YU Z, LENNON VA: Mechanism of iv. immune globulin therapy in antibody-mediated autoirnmune disease. N. Engl. J. Med. (1999) 340:227–228.
   Google Scholar
• SHOENFELD Y, FISHMAN P. y-globulin inhibits tumour spread in mice. Int. Immunol. (1999) 11:1247–1252.
   PubMed Web of Science ®Google Scholar
• PRASAD NKA, PAPOFF G, ZEUNER A et al.: Therapeutic preparations of normal polyspecific IgG (WIG) induce apoptosis in human lymphocytes and monocytes, a novel mechanism of action of WIG involving the Fas apoptotic pathway. J. Immunol. (1998) 161:3781–3790.
   PubMed Web of Science ®Google Scholar
• ••A clear and comprehensive review.
   Google Scholar
• VIARD I, WEHRIL P, BULLANI R et al.: Inhibition of toxicepidermal necrolysis by blockade of CD95 with human iv. inununoglobulin. Science (1998) 282:490–493.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, OSTERBORG A, BRITTINGER G et al.:Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's malignant lymphomas: a Phase II multicenter study. J. Clin. Oncol. (1998) 16:3257–3263
   PubMed Web of Science ®Google Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK et al.: Anti-idiotype antibodies can induce long-term complete remission in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92:1184–1190.
   PubMed Web of Science ®Google Scholar
• ••This excellent paper reports data from clinical use.
   Google Scholar
• MALLONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• BERINSTEIN NL, GRILLO-LOPEZ AJ, WHITE CA et al.:Association of serum Retuximab (IDEC-C2B8) concen-tration and antitumour response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1998) 9:995–1001.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, HAIOUN C, KETTERER N et al.: Rituximab(anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92: 1927-1932.
   Google Scholar
• BRYD JC, WASELENKO JK, MANEATIS TJ et al.: Rituximabtherapy in hematologic malignancy patients with circulating blood tumour cells: association with increased infusion-related side effects and rapid blood tumour clearance. J. Clin. Oncol. (1999) 17:791–795.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymhomas with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. (1999) 17:268–276.
   PubMed Web of Science ®Google Scholar
• NGUYEN DT, AMESS JA, DOUGHTY H, HENDRY L, DIAMOND LW: IDEC-C2B8 antiCD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of 48 patients. Eur. J. Haematol. (1999) 62:76–82.
   PubMed Web of Science ®Google Scholar
• STONE MJ, SAUSVILLE EA, FAY JW et al.: A Phase I studyof bolus versus continuous infusion of antiCD19 inimunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 88:1188–1197.
   PubMed Web of Science ®Google Scholar
• MULTANI PS, O'DAY S, NADLER LM, GROSSBARD ML: Phase II clinical trial of bolus infusion of antiB4 blocked ricin inimunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. (1998) 4:2599–2604.
   PubMed Web of Science ®Google Scholar
• GROSSBARD ML, NIEDZWIECKI J, NADLER LM et al.: AntiB4 blocked ricin (anti-B4bR) adjuvant therapy post autologous bone marrow transplantation: a Phase BI intergroup study. Proc. ASCO (1998) 17:3a.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS I et al.: Iodine-131antiBl radioirnmunotherapy for B-cell lymphomas. J. Clin. Oncol. (1996) 14:1974–1981.
   PubMed Web of Science ®Google Scholar
• DEB N, GORIS M, TRISLER K et al.: Treatment ofhormone-refractory prostate cancer with 90Y-YT-356 monoclonal antibody. Clin. Cancer Res. (1996) 2:1289–1297.
   PubMed Web of Science ®Google Scholar
• JUWEID M, SHARKEY R, MARLOWITZ A et al.: Treatmentof non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an antiCD22 monoclonal antibody. Cancer Res. (1995) 55:5899s–5907s.
   Google Scholar
• WHITE C, HALPERN S, PARKER B et al.: Radioirnmuno-therapy of relapsed B-cell lymphoma with Yttrium-90 anti-idiotype monoclonal antibodies. Blood (1996) 87:3640–3647.
   PubMed Web of Science ®Google Scholar
• STEVENSON FK: Vaccine strategies in indolent lymphomas. In: American Society of Hematology Education Program Book. Schechter GP, Hoffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999):312–318.
   Google Scholar
• SHERR C: Cancer cell cycles. Science (1996) 274:1672.
   PubMed Web of Science ®Google Scholar
• ISAACSON PG: Recent developments in our understanding of gastric lymphomas. Am. J. Surg. Pathol. (1999) 20:S1–7.
   Google Scholar
• ••The best review within this field to date.
   Google Scholar
• COLLINS RD: Is clonality equivalent to malignancy: specifically, is immunogjobulin gene rearrangement diagnostic of malignant lymphoma? Hum. Pathol. (1997) 28:757–759.
   Web of Science ®Google Scholar
• ANDERSON WF: Human gene therapy. Nature (1998)392:25–27.
   PubMed Web of Science ®Google Scholar
• WIVEL NA, WILSON JM: Methods of gene delivery. Hematol. Oncol. Clin. North Am. (1998) 12:483–501.
   PubMed Web of Science ®Google Scholar
• BOUVET M, ELLIS LM, NISHIZAKI M et al Adenovirus mediated wild type p53 gene transfer downregulates vascular endothelial growth factor expression and Exp. Opin. Pharmacother. (2000) 1(4) inhibits angiogenesis in human colon cancer. Cancer Res (1998) 58:2288–2292.
   Google Scholar
• ROTH JA, SWISHER SG, BOUVET M, MERRITT JA: p53gene replacement therapy in lung cancer. Adv. Oncol. (1998) 14:3–7.
   Google Scholar
• DIBER MS, ABEDI MR, BJORKSTRAND B et al.: Suicidegene therapy for plasma cell tumours. Blood (1996) 88:2192–2200.
   PubMedGoogle Scholar
• TIBERGHIEN P: Suicide gene for control of graft-versus-host disease. Curr. Opin. Hematol. (1998) 5:478–482.
   PubMedGoogle Scholar
• BONINI C, BORDIGNON C: Suicide gene therapy for control of graft-versus -host disease. Immunologist (1999) 7:93–96.
   Google Scholar
• •An excellent description of the technique.
   Google Scholar
• HO PTC, PARKINSON DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. (1997) 24:1–17.
   PubMed Web of Science ®Google Scholar
• VAERMAN JL, MOUREAU P, DELDIME F et al.: Antisenseoligodeoxyribinucleotides suppress hematologic cell growth through stepwise release of deoxyribinucleo-tides. Blood (1997) 90:331–339.
   PubMed Web of Science ®Google Scholar
• KRONENWETT R, STEILD U, KIRCH M, SCZAKIEL G, HASSR: Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood (1998) 91:852–862.
   PubMed Web of Science ®Google Scholar
• ALBRECHT T, SCHWALB R, HENKES M et al.: Primaryproliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br. J. Haematol. (1996) 95:501–507.
   PubMed Web of Science ®Google Scholar
• BHATIA R, VERFAILLIE CM: Inhibition of BCR-abl expression with antisense oligodeoxynucleotides restores 13-1 integrin-mediated adhesion and prolifera-tion inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood (1998) 91:3414–3422.
   PubMed Web of Science ®Google Scholar
• LOWENBERG B, DOWNING JR, BURNETT A: Medical progress: acute myeloid leukemia. N. Engl . J. Med. (1999) 341:1051–1062.
   PubMed Web of Science ®Google Scholar
• MENDOZA RB, CANTWELL MJ, KIPPS TJ. Immunostimu-latory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol. (1997) 159:5777–5781.
   Google Scholar
• KATO K, CANTWELL MJ, SHARMA S, KIPPS TJ: Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia. J. Clin. Invest. (1998) 101:1133–1141.
   PubMed Web of Science ®Google Scholar
• DU MQ, XU CF, DISS TC, PENG HZ, WOTHERSPOON AC,ISAACSON PG: Intestinal dissemination of gastric mucosa associated lymphoid tissue-lymphoma. Blood (1996) 88:4445–4451.
   PubMed Web of Science ®Google Scholar
• ZUCCA E, BERTONI F, ROGGERO E et al Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N. Engl. J. Med. (1998) 338:804–810.
   PubMed Web of Science ®Google Scholar
• APPELMELK BJ, FALLER G, CLAEYS D, KIRCHNER T, WANDENBRUCKE-GRAULS CMJE: Bugs on trial, the case of Helicobacter pylori and autoinamunity. Immunol. Today (1998) 19: 296–299.
   PubMedGoogle Scholar
• JONSSON V, WIIK A, HOU-JENSEN K et al.: Autoinamunity and extranodal lymphocytic infiltrates in lymphopro-liferative disorders. J. Intern. Med. (1999) 245:277–286.
   PubMed Web of Science ®Google Scholar
• ROLSTON KV, BERKEY P, BODEY GP et al.: A comparison of innipenem to ceftazidime with or without arnikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med. (1992) 152:283–291.
   PubMed Web of Science ®Google Scholar
• BODEY GP: Empirical antibiotic therapy for fever inneutropenic patients. Clin. Infect. Dis. (1993) 17\(Suppl. 2):S378–384.
   Google Scholar
• KLASTERSKY J, CAPPEL R, DANEAU D: Clinical signifi-cance of in vitro synergism between combination antibiotics in Gram-negative infections. Antimicrob. Agent Chemother. (1972) 2:470–475.
   PubMed Web of Science ®Google Scholar
• KERN WV FOR THE INTERNATIONAL ANTIMICROBIALTHERAPY COOPRATIVE GROUP OF EORTC: Oral versus iv. empirical therapy for fever in cancer patients with an expected short duration of granulocytopenia. Proc. ICAAC (1998). Abstract 18.
   Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empiric therapy in patients with persisting fever and neutropenia. National Institute of Allergy and Infectious diseases Mycosis study group. N. Engl. J. Med. (1999) 340:764–771.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Prevention and management of invasive fungal infections. In: American Society of Hematology Education Program Book. Schechter GP, Hoffman R, Schrier SL, Bajus JL (Eds.), Am. Soc. Hematol. Soc., New Orleans, Washington DC, USA (1999):533–535.
   Google Scholar
• WILLIAMS C, COYLE D, GRAY J et al.: European School of Oncology advisory report to the Commission of the European Communities for 'Europe against cancer programme' cost-effectiveness in cancer care. Eur. J. Cancer (1995) 31:1410–1424.
   Web of Science ®Google Scholar
• DRUMMOND MF. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ. (1992) 1:85–92.
   Google Scholar
• KLASTERSKY J: Current attitudes for therapy of febrileneutropenia with consideration to cost-effectiveness. Curr. Opin. Oncol. (1998) 10:284–290.
   PubMedGoogle Scholar
• •This is an update of the previous study of the author.
   Google Scholar
• JONSSON V, MORK HANSEN M, LJUNGMAN P, KAASA S:Pharmacoeconomic considerations in treating patients with acute leukaemia. PharmacoEconomics (1999) 15:167–178.
   PubMed Web of Science ®Google Scholar
• TORRANCE GW: Designing and conduction cost-utilityanalysis. In: Quality of Life and Pharmacoeconomics in Clinical Trials. Spilker B (Ed.), Lippincott-Raven, Philadel-phia, USA (1996):1105–1111. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• FAYERS PM, HAND DJ: Generalisation from Phase ifi clinical trials: survival, quality of life and health economics. Lancet (1997) 350:1025–1027.
   PubMed Web of Science ®Google Scholar